Citations

Clear

3030 citation(s) found for "Susan, M".

Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Chao, Chieh‐Ju , Jeong, Jiwoong , Farina, Juan M. , Seri, Amith Reddy , Barry, Timothy , Newman, Hana , Campany, Megan , Abdou, Merna , O’Shea, Michael , Smith, Sean D. , Abraham, Bishoy, Hosseini, Seyedeh Maryam , Wang, Yuxiang , Lester, Steven J., Alsidawi, Said , Wilansky, Susan , Steidley, Eric, Rosenthal, Julie , Appleton, Christopher P., Shen, Win‐Kuang , Grogan, Martha , Kane, Garvan C. , Oh, Jae K. , Patel, Bhavik N. , Arsanjani, Reza , Banerjee, Imon , O’Shea, Michael , Chao, Chieh-Ju , Jeong, Jiwoong Jason, Farina, Juan M , Seri, Amith R, Barry, Timothy , O'Shea, Michael, Smith, Sean , Hosseini, Seyedeh Maryam , Lester, Steven, Alsidawi, Said , Arsanjani, Reza , Banerjee, Imon , Li, James , O’Shea, Michael, Abraham, Bishoy

Mayo Clinic

Journal of Imaging | February 20, 2023 | Volume: 9 | Issue: 2 | Pages: 48

10.3390/jimaging9020048 | PMID 36826967 Get It

Aims:Increased left ventricular (LV) wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results: Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 and 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4-chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: HCM: 0.93, CA: 0.90, and HTN/other: 0.92). Conclusion: The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.
Predictive Value of Preresidency Academic Metrics on Resident Publication Potential
Catalano, Dominic J. , Bisco, Susan E. , Lohse, Christine M. , Carlson, Matthew L., Stokken, Janalee K. , Yin, Linda X , Carlson, Matthew L , Yin, Linda X. , Carlson, Matthew L.

Mayo Clinic

OTO Open | February 17, 2023 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/oto2.34 | PMID 36998548 Get It

AbstractObjectiveOtolaryngology residency is highly competitive, and applicant academic metrics are scrutinized. The predictive value of preresidency academic metrics on applicants’ future research productivity and career aspirations remains largely undefined.Study DesignRetrospective cohort studySettingAcademic otolaryngology department, 2014 to 2015.MethodsApplicant demographics, publication history, and United States Medical Licensing Examination (USMLE) scores were downloaded from Electronic Residency Application Service archives. Publications during residency were tallied from all PubMed articles indexed between July 1, 2015 and June 30, 2020. Postresidency career paths were examined by 2 investigators (D.J.C. and L.X.Y.) using Google searches with an emphasis on program websites, Doximity, and LinkedIn profiles. Associations with publication potential and postresidency positions were evaluated with Spearman rank correlation coefficients and Kruskal‐Wallis, Wilcoxon rank sum, and χ2 tests.ResultsOf 321 applicants, 226 (70%) matched, and 205 (64%) completed residency by June 2020. Matched residents published a median of 4 (range: 0‐41) manuscripts during residency. USMLE scores, Alpha Omega Alpha status, and the number of preresidency publications did not significantly correlate with publication potential during residency. The number of research experiences had a significant positive correlation with publications during residency (p < 0.001). Asian race (p = 0.002) and geographical region of residency (p < 0.001) also had significant associations with publication potential. Of the 205 graduates, 118 (58%) enrolled in fellowship. Age and female sex (74% vs 48%; p = 0.002) were the only factors significantly associated with pursuing a fellowship.ConclusionIn otolaryngology, not all preresidency academic metrics are associated with publication potential during residency or propensity for fellowship training. Programs should not use academic metrics alone to predict an applicant's future research productivity or career trajectory.
Incidence of Glaucoma-Related Adverse Events in the First 5 Years After Pediatric Lensectomy
Bothun, Erick D. , Repka, Michael X. , Kraker, Raymond T. , Leske, David A. , Li, Zhuokai , Astle, William F., Holmes, Jonathan M. , Group, Pediatric Eye Disease Investigator, Wallace, David K. , Enyedi, Laura B. , Jones, Sarah K., Hug, Denise, Stahl, Erin D., Dent, Rebecca J., Kong, Lingkun , Wang, Serena , Gallerson, Bryan K., Hutchinson, Amy K., Lenhart, Phoebe D. , Brower, Judy, Morrison, David G., Ruark, Scott T., Mets-Halgrimson, Rebecca, Yoon, Hawke , Hamidullah, Aaliyah, Anderson, Jill S., Holleschau, Ann M., Superstein, Rosanne , Bélanger, Caroline, Fallaha, Nicole, Hamel, Patrick , Thibeault, Maryse, Tamkins, Susanna M. , Park, Hee-Jung S., Trumler, Anya A., Liu, Xiaonong, Sanders, Emi , McOwen, Diana C., Gray, Michael E. , Yang, Michael B. , Bowman, Corey S., Galvin, Jennifer, Therriault, Margaret, Smith, Heather , Whitaker, Michele E., Örge, Faruk , Grigorian, A. Paula, Baird, Alicia M., Strominger, Mitchell B. , Klein, Shelley, Kemmer, Jacquelyn D., Neiman, Alexandra E., Mendoza, Myra N., Frohwein, Jill J., Bremer, Don L., Cassady, Cybil, Golden, Richard P., Jordan, Catherine O., Oravec, Sara A., Yanovitch, Tammy L. , Lunsford, Keven, Nye, Christina, Shea, Caroline, Stillman, SueAnn M., Iderstine, Stephen C. Van, Robertson, Elisa, Cruz, Oscar A., Ghadban, Rafif, Govreau, Dawn, Longmuir, Susannah Q. , Shan, Xiaoyan, Taylor, Kate , Powell, Christine, Hammond, Benjamin P., Gearinger, Matthew D., Czubinski, Andrea, Salvin, Jonathan, Fisher, Alicia, Lee, Katherine A., Brooks, Daniel , Schweinler, Bonita R., Sala, Nicholas A., Sala, Allyson M., Summers, Allison I. , Karr, Daniel J. , Wilson, Lorri B., Rauch, Paula K., O’Hara, Mary, Gandhi, Nandini, Hashmi, Tania, Colburn, Jeffrey, Dittman, Eileen, Whitfill, Charles R., Wheeler, Amy M., McCourt, Emily A. , Singh, Jasleen , Welnick, Nanastasia, Azar, Nathalie F., Baker, Joseph, Droste, Patrick J. , Peters, Robert J., Hilbrands, Jan, Pineles, Stacy L., Bernardo, Marianne J., Peterson, Edward, Peterson, Charla H., Kumar, Kartik , Melese, Ephrem, Lingua, Robert W., Grijalva, Jeff, Crouch, Earl R., Crouch, Earl R., Ventura, Gaylord, Anninger, William, Benson, Shawn L., Karp, Karen A. , Smith, Jordana M., Brickman-Kelleher, Jill, Ticho, Benjamin H., Khammar, Alexander J., Clausius, Deborah A., Guo, Suquin, Chamberlain, Carolyn, Schloff, Susan, Madigan, William P., Burkman, Donna, Ramsey, Jean E., McConnell, Kate H. , Friedman, Ilana, Rosado, José , Sauberan, Donald P., Hemberger, Jody C., Davis, Patricia L., Rudaitis, Indre, Lowery, Robert S., Cupit, Shawn, Mohney, Brian G., Wernimont, Suzanne M., Neilsen, Rebecca A., Baran, Francine, Gladstone, Amy, Smith, Justin , Mellott, Mei, Kieser, Troy, Erzurum, S. Ayse , Colon, Beth, Shah, Birva, Quebbemann, Micaela, Austin, Darrell S., Boyle, Nicole M., Conner, Courtney L., Chandler, Danielle L. , Donahue, Quayleen, Fimbel, Brooke P., Robinson, Julianne L., Hercinovic, Amra, Hoepner, James E., Kaplon, Joseph D., Melia, Michele , Ortiz, Gillaine, Woodard, Victoria C., Stutz, Kathleen M., Sutherland, Desirae R. , Everett, Donald F., Diener‐West, Marie , Baker, John D., Davis, Barry R. , Phelps, Dale L. , Poff, Stephen W., Tychsen, Lawrence , Bradfield, Yasmin S., Foster, Nicole C. , Plager, David A. , Salchow, Daniel J. , Silver, Jayne L., Weise, Katherine K., Verderber, Lisa C. , Dean, Trevano W., Yen, Kimberly G., Campomanes, Alejandra G. de Alba , Young, Marielle P. , Rahmani, Bahram , Haider, Kathryn M. , Whitehead, George F., Lambert, Scott R. , Kurup, Sudhi P. , Kraus, Courtney L. , Wu, Rui, Hatt, Sarah R. , Freedman, Sharon F. , Cotter, Susan A. , Group, Pediatric Eye Disease Investigator, Prakalapakorn, Sasapin Grace , Ranaivo, Hantamalala Ralay , Areaux, Raymond G. , Chang, Ta Chen , Traboulsi, Elias I. , Ghasia, Fatema F. , Chen, Vicki, Rogers, David L. , LaRoche, G. Robert, Larson, Scott A. , Clarke, Michael W. , Hendricks, Dorothy H. , Jin, Jing , Brooks, Daniel, Rauch, Paula K., Baker, Joseph, Peterson, Edward, Crouch, Earl R., Suh, Donny Won , Christiansen, Stephen P. , Herlihy, Erin P. , Beck, Roy W. , Henderson, Robert J. , Saunders, Richard Anthony , Birch, Eileen E. , Manny, Ruth E. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | February 16, 2023 | Volume: 141 | Issue: 4 | Pages: 324

10.1001/jamaophthalmol.2022.6413 | PMID 36795393 Get It

ImportanceGlaucoma can develop following cataract removal in children.ObjectiveTo assess the cumulative incidence of glaucoma-related adverse events (defined as glaucoma or glaucoma suspect) and factors associated with risk of these adverse events in the first 5 years after lensectomy prior to 13 years of age.Design, Setting, and ParticipantsThis cohort study used longitudinal registry data collected at enrollment and annually for 5 years from 45 institutional and 16 community sites. Participants were children aged 12 years or younger with at least 1 office visit after lensectomy from June 2012 to July 2015. Data were analyzed from February through December 2022.ExposuresUsual clinical care after lensectomy.Main Outcomes and MeasuresThe main outcomes were cumulative incidence of glaucoma-related adverse events and baseline factors associated with risk of these adverse events.ResultsThe study included 810 children (1049 eyes); 443 eyes of 321 children (55% female; mean [SD] age, 0.89 [1.97] years) were aphakic after lensectomy, and 606 eyes of 489 children (53% male; mean [SD] age, 5.65 [3.32] years) were pseudophakic. The 5-year cumulative incidence of glaucoma-related adverse events was 29% (95% CI, 25%-34%) in 443 eyes with aphakia and 7% (95% CI, 5%-9%) in 606 eyes with pseudophakia; 7% (95% CI, 5%-10%) of aphakic eyes and 3% (95% CI, 2%-5%) of pseudophakic eyes were diagnosed as glaucoma suspect. Among aphakic eyes, a higher risk for glaucoma-related adverse events was associated with 4 of 8 factors, including age less than 3 months (vs ≥3 months: adjusted hazard ratio [aHR], 2.88; 99% CI, 1.57-5.23), abnormal anterior segment (vs normal: aHR, 2.88; 99% CI, 1.56-5.30), intraoperative complications at time of lensectomy (vs none; aHR, 2.25; 99% CI, 1.04-4.87), and bilaterality (vs unilaterality: aHR, 1.88; 99% CI, 1.02-3.48). Neither of the 2 factors evaluated for pseudophakic eyes, laterality and anterior vitrectomy, were associated with risk of glaucoma-related adverse events.Conclusions and RelevanceIn this cohort study, glaucoma-related adverse events were common after cataract surgery in children; age less than 3 months at surgery was associated with elevated risk of the adverse events in aphakic eyes. Children with pseudophakia, who were older at surgery, less frequently developed a glaucoma-related adverse event within 5 years of lensectomy. The findings suggest that ongoing monitoring for the development of glaucoma is needed after lensectomy at any age.
Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Wang, Chen , Block, Matthew S. , Cunningham, Julie M. , Sherman, Mark E. , McCauley, Bryan M. , Armasu, Sebastian M. , Vierkant, Robert A. , Group, for the Australian Ovarian Cancer Study, Talhouk, Aline , Ramus, Susan J. , Pejovic, Nadja , Jorgensen, Brooke D. , Garsed, Dale W. , Anglesio, Michael S. , Widschwendter, Martin , Bowtell, David D.L. , Goode, Ellen L. , Traficante, Nadia , Talhouk, Aline , Ramus, Susan J , Pejovic, Nadja , Köbel, Martin , Jorgensen, Brooke D , Garsed, Dale W , Fereday, Sian , Doherty, Jennifer A , Ariyaratne, Dinuka , Anglesio, Michael S , Widschwendter, Martin , Pejovic, Tanja B. , Bosquet, Jesus Gonzalez , Bowtell, David D , Winham, Stacey J , Goode, Ellen L , Vierkant, Robert A , Wang, Chen , Sherman, Mark E , Traficante, Nadia , Group, for the Australian Ovarian Cancer Study, Köbel, Martin , Fereday, Sián , Doherty, Jennifer A. , Ariyaratne, Dinuka , Bosquet, Jesús González , Winham, Stacey J.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 15, 2023 | Volume: 32 | Issue: 4 | Pages: 542-549

10.1158/1055-9965.epi-22-0941 | PMID 36790339 Get It

Abstract Background: Better understanding of prognostic factors in tubo-ovarian high-grade serous carcinoma (HGSC) is critical, as diagnosis confers an aggressive disease course. Variation in tumor DNA methylation shows promise predicting outcome, yet prior studies were largely platform-specific and unable to evaluate multiple molecular features. Methods: We analyzed genome-wide DNA methylation in 1,040 frozen HGSC, including 325 previously reported upon, seeking a multi-platform quantitative methylation signature that we evaluated in relation to clinical features, tumor characteristics, time to recurrence/death, extent of CD8+ tumor-infiltrating lymphocytes (TIL), gene expression molecular subtypes, and gene expression of the ATP-binding cassette transporter TAP1. Results: Methylation signature was associated with shorter time to recurrence, independent of clinical factors (N = 715 new set, hazard ratio (HR), 1.65; 95% confidence interval (CI), 1.10–2.46; P = 0.015; N = 325 published set HR, 2.87; 95% CI, 2.17–3.81; P = 2.2 × 10−13) and remained prognostic after adjustment for gene expression molecular subtype and TAP1 expression (N = 599; HR, 2.22; 95% CI, 1.66–2.95; P = 4.1 × 10−8). Methylation signature was inversely related to CD8+ TIL levels (P = 2.4 × 10−7) and TAP1 expression (P = 0.0011) and was associated with gene expression molecular subtype (P = 5.9 × 10−4) in covariate-adjusted analysis. Conclusions: Multi-center analysis identified a novel quantitative tumor methylation signature of HGSC applicable to numerous commercially available platforms indicative of shorter time to recurrence/death, adjusting for other factors. Along with immune cell composition analysis, these results suggest a role for DNA methylation in the immunosuppressive microenvironment. Impact: This work aids in identification of targetable epigenome processes and stratification of patients for whom tailored treatment may be most beneficial.
Association of Polygenic Score and the involvement of Cholinergic and Glutamatergic Pathways with Lithium Treatment Response in Patients with Bipolar Disorder
Amare, Azmeraw T. , Thalamuthu, Anbupalam , Schubert, Klaus Oliver , Fullerton, Janice M. , Heilbronner, Urs , Hsu, Yi‐Hsiang , Shekhtman, Tatyana , Adli, Mazda , Akula, Nirmala , Akiyama, Kazufumi , Ardau, Raffaella , Aubry, Jean‐Michel , Bhattacharjee, Abesh Kumar, Benabarre, Antoni, Bengesser, Susanne , Birner, Armin , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Cruceanu, Cristiana , Dalkner, Nina , Zompo, Maria Del , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Fallgatter, Andreas J. , Stegmaier, Sophia, Biere, Silvia, Petrova, Kristiyana, Schuster, Ceylan, Heilbronner, Maria , Kálmán, János , Kohshour, Mojtaba Oraki , Schaupp, Sabrina K. , Senner, Fanny , Vogl, Thomas , Anghelescu, Ion‐George , Arolt, Volker , Dietrich, Detlef E. , Figge, Christian, Jäger, Markus , Juckel, Georg , Reimer, Jens , Schmauß, Max, Konrad, Carsten , Hagen, Martin von, Zimmermann, Jörg, Andlauer, Till F. M. , Bermpohl, Felix , Kraft, Vivien , Gryaznova, Anna, Yildiz, Cüneyt , Kircher, Tilo , Gade, Katrin , Trost, Sarah , Lambert, Martin , Rohenkohl, Anja , Grof, Paul , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Ferensztajn‐Rochowiak, Ewa , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , O’Donovan, Claire , Pisanu, Claudia , Potash, James B. , Schalling, Martin , Schweizer, Barbara , Severino, Giovanni , Shilling, Paul D. , Shimoda, Kazutaka , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Maj, Mario , Vieta, Eduard , Veeh, Julia, Witt, Stephanie H. , Zandi, Peter P. , Bauer, Michael , Clark, Scott R. , Amare, Azmeraw , Fullerton, Janice M , Papiol, Sergi , Heilbronner, Urs , Biernacka, Joanna , Marie-Claire, Cynthia , Chen, Hsi-Chung , Cichon, Sven , Cruceanu, Cristiana , Czerski, Piotr , Del Zompo, Maria , Etain, B , Jamain, Stéphane , Forstner, Andreas J , Frye, Mark , Garnham, Julie , Goes, Fernando , Grigoroiu-Serbanescu, Maria , Kalman, Janos , Schulte, Eva , Wiltfang, Jens , Andlauer, Till , Kraft, Vivien , Hauser, Joanna , Kuo, Po-Hsiu , Kittel-Schneider, Sarah , Kusumi, Ichiro , Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Nöthen, Markus M , Novak, Tomas , Pisanu, Claudia , Reif, Andreas , Reininghaus, Eva , Rouleau, Guy Armand , Schalling, Martin , Schofield, Peter R , Severino, Giovanni , Shimoda, Kazutaka , Squassina, Alessio , Stopkova, Pavla , Turecki, Gustavo , Vieta, E , Witt, Stephanie H , Zandi, Peter P , Alda, Martin , Rietschel, Marcella , McMahon, Francis , Millischer, Vincent , Clark, Scott , Thalamuthu, Anbupalam , Kircher, Tilo T J , Schubert, Klaus Oliver , Mitjans, Marina , Ahmed, Muktar Beshir , Hartmann, Simon , Papiol, Sergi , Degenhardt, Franziska , Tekola‐Ayele, Fasil , Hou, Liping , Arias, Bárbara , Backlund, Lena , Bellivier, Frank , Benabarre, Antoni , Biernacka, Joanna M. , Chen, Hsi‐Chung , Czerski, Piotr M. , Dalkner, Nina , DePaulo, J Raymond , Étain, Bruno , Jamain, Stéphane , Falkai, Peter , Grigoroiu‐Serbânescu, Maria , Ethofer, Thomas , Adorjan, Kristina , Budde, Monika , Reich‐Erkelenz, Daniela , Schulte, Eva C. , Dannlowski, Udo , Lang, Fabian U. , Spitzer, Carsten , Schmitt, Andrea , Wiltfang, Jens , Zimmermann, Jörg , Fischer, André , Matura, Silke , Gryaznova, Anna, Falkenberg, Irina , Schmidt, Julia Katharina , Koch, Marius, Haussleiter, Ida Sibylle , Hashimoto, Ryota , Herms, Stefan , Hoffmann, Per , Jiménez, Esther , Kuo, Po‐Hsiu , Kato, Tadafumi , Kelsoe, John R , König, Barbara , Leboyer, Marion , Tortorella, Alfonso , Manchia, Mirko , Martinsson, Lina , McElroy, Susan L. , Colom, Francesc , Monteleone, Palmiero , Nievergelt, Caroline M , Novák, Tomáš , Ozaki, Norio , Pfennig, Andrea , Reif, Andreas , Rybakowski, Janusz K , Schofield, Peter R. , Squassina, Alessio , Stopková, Pavla , Turecki, Gustavo , Wright, Adam, Mitchell, Philip B , Alda, Martin , McMahon, Francis J. , Schulze, Thomas , Baune, Bernhard

Mayo Clinic

No container title available | February 14, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2580252/v1 | PMID 36824922 Get It

Abstract Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li+PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li+PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi+Gen: N=2,367) and replicated in the combined PsyCourse (N=89) and BipoLife (N=102) studies. The associations of Li+PGS and lithium treatment response — defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P<����������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
Design and quality control of large-scale two-sample Mendelian randomization studies
Haycock, Philip , Borges, Maria Carolina , Burrows, Kimberley , Harrison, Sean , Burgess, Stephen , Chang, Xuling , Khankari, Nikhil K. , Tsilidis, Kostas K, Gaunt, Tom R. , Hemani, Gibran , Zheng, Jie , Truong, Thérèse , Law, Matthew H. , Mariosa, Daniela , Hung, Rayjean J, Smith, George Davey , Relton, Caroline L. , Martin, Richard M. , Peters, Ulrike , Rice, Terri, Gallinger, Steve, Cornish, Alex J. , Vijayakrishnan, Jayaram , Wrensch, Margaret , Korat, Andres V Ardisson , Wheeler, Bill, Nilsson, Björn , Smith, Caren E. , Riadi, David, Claus, Elizabeth B. , Hosnijeh, Ng, Irene Oi‐Lin , Passow, Jeanette E, Han, Jiali , Schildkraut, Joellen M. , Wiemels, Joseph L. , Yang, Keming , Wu, Lang , Boutron, Marie-Christine, Iles, Mark M. , Stanulla, Martin , Gaudet, Mia M., Lenha, Mobuchon, Camp, Nicki J, Sham, Pak C. , Brennan, Paul , Jenkins, Robert B. , Diskin, Sharon J. , Berndt, Sonja I. , Tsavachidis, Spiridon, Channock, Stephen J., Galesloot, Tessel E. , Haycock, Philip , Harrison, Sean , Chang, Xuling , Zheng, Jie , Law, Matthew H , Birmann, Brenda M , Mariosa, Daniela , Zheng, Wei , Davey Smith, George , Borges, Maria C , Martin, Richard M , Iles, Mark M , Truong, Therese , Lemaître, Rozenn N. , Westra, Jason , Tsilidis, Kostas K, O’Mara, Tracy A. , Spurdle, Amanda B. , Slager, Susan L. , Birmann, Brenda M. , Hosnijeh, Fatemeh Saberi , Amos, Christopher I. , Hung, Rayjean J, Zheng, Wei , Gunter, Marc J. , Tintle, Nathan , Cheng, Iona C. , Jenkins, Mark A. , Sud, Amit , Johansson, Mattias , Norman, Aaron D. , Klein, Alison P. , Clay‐Gilmour, Alyssa , Franke, André , Heng, Chew‐Kiat , Song, Ci , Ellinghaus, Eva , Ostroumova, Evgenia , Vathaire, Florent de , Cugliari, Giovanni , Matullo, Giuseppe , Cerhan, James R. , Passow, Jeanette E. Eckel, Foo, Jia Nee , Liu, Jianjun , Barnholtz‐Sloan, Jill S. , Maris, John M. , Hemminki, Kari , Kiemeney, Lambertus A. , Ámundadóttir, Laufey T. , Stern, Marc‐Henri , Purdue, Mark P. , Bondy, Melissa L. , Guénel, Pascal , Taylor, Philip R. , Gharahkhani, Puya , Ostrom, Quinn T. , Stolzenberg‐Solomon, Rachael Z. , Dorajoo, Rajkumar , Houlston, Richard S. , Enroth, Stefan , Harrison, Tabitha A. , Gyllensten, Ulf B , Vijai, Joseph , Shi, Yufang , Yang, Wenjian , Lin, Yi , Van Den Eeden, Stephen K

Mayo Clinic

International Journal of Epidemiology | February 11, 2023 | Volume: 52 | Issue: 5 | Pages: 1498-1521

10.1093/ije/dyad018 | PMID 38587501 Get It

Abstract Background Mendelian randomization (MR) studies are susceptible to metadata errors (e.g. incorrect specification of the effect allele column) and other analytical issues that can introduce substantial bias into analyses. We developed a quality control (QC) pipeline for the Fatty Acids in Cancer Mendelian Randomization Collaboration (FAMRC) that can be used to identify and correct for such errors. Methods We collated summary association statistics from fatty acid and cancer genome-wide association studies (GWAS) and subjected the collated data to a comprehensive QC pipeline. We identified metadata errors through comparison of study-specific statistics to external reference data sets (the National Human Genome Research Institute-European Bioinformatics Institute GWAS catalogue and 1000 genome super populations) and other analytical issues through comparison of reported to expected genetic effect sizes. Comparisons were based on three sets of genetic variants: (i) GWAS hits for fatty acids, (ii) GWAS hits for cancer and (iii) a 1000 genomes reference set. Results We collated summary data from 6 fatty acid and 54 cancer GWAS. Metadata errors and analytical issues with the potential to introduce substantial bias were identified in seven studies (11.6%). After resolving metadata errors and analytical issues, we created a data set of 219 842 genetic associations with 90 cancer types, generated in analyses of 566 665 cancer cases and 1 622 374 controls. Conclusions In this large MR collaboration, 11.6% of included studies were affected by a substantial metadata error or analytical issue. By increasing the integrity of collated summary data prior to their analysis, our protocol can be used to increase the reliability of downstream MR analyses. Our pipeline is available to other researchers via the CheckSumStats package (https://github.com/MRCIEU/CheckSumStats).
Baseline characteristics of the North American prodromal Synucleinopathy cohort
Lim, Miranda M. , Keil, Allison , Postuma, Ronald B. , Pelletier, Amélie , Gagnon, Jean‐François , Louis, Erik K. St. , Forsberg, Leah K. , Fields, Julie A. , Huddleston, Daniel E. , Howell, Michael J. , McLeland, Jennifer , Criswell, Susan R. , Miglis, Mitchell G. , Lee‐Iannotti, Joyce , Ju, Yo‐El S. , Summers, Rebekah L. S. , Ligman, Brittany R. , MacKinnon, Colum D. , Elliott, Jonathan E , Lim, Miranda M , Keil, Allison T , Postuma, Ronald B , Gagnon, Jean-François , St Louis, E K , Fields, Julie A , Huddleston, Daniel E , Bliwise, Donald L , Howell, Michael J , Criswell, Susan R , During, Emmanuel , Miglis, Mitchell G , Shprecher, David , Lee-Iannotti, Joyce K , Boeve, Brad , Ju, Yo-El S , Elliott, Jonathan E. , Bliwise, Donald L. , Avidan, Alon Y. , Schenck, Carlos H. , Videnovic, Aleksandar , Shprecher, David , Boeve, Bradley F.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 8, 2023 | Volume: 10 | Issue: 4 | Pages: 520-535

10.1002/acn3.51738 | PMID 36751940 Get It

Abstract Objective Rapid eye movement (REM) sleep behavior disorder (RBD) is widely considered a prodromal synucleinopathy, as most with RBD develop overt synucleinopathy within ~10 years. Accordingly, RBD offers an opportunity to test potential treatments at the earliest stages of synucleinopathy. The North American Prodromal Synucleinopathy (NAPS) Consortium has created a multisite RBD participant, primarily clinic‐based cohort to better understand characteristics at diagnosis, and in future work, identify predictors of phenoconversion, develop synucleinopathy biomarkers, and enable early stage clinical trial enrollment. Methods Participants ≥18 years of age with overnight polysomnogram‐confirmed RBD without Parkinson's disease, dementia, multiple system atrophy, or narcolepsy were enrolled from nine sites across North America (8/2018 to 4/2021). Data collection included family/personal history of RBD and standardized assessments of cognitive, motor, sensory, and autonomic function. Results Outcomes are primarily reported based on sex (361 total: n = 295 male, n = 66 female), and secondarily based on history of antidepressant use ( n = 200 with, n = 154 without; with correction for sex differences) and based on extent of synucleinopathy burden ( n = 56 defined as isolated RBD, n = 305 defined as RBD+ [i.e., exhibiting ≥1 abnormality]). Overall, these participants commonly demonstrated abnormalities in global cognition (MoCA; 38%), motor function (alternate tap test; 48%), sensory (BSIT; 57%), autonomic function (orthostatic hypotension, 38.8%), and anxiety/depression (BAI and PHQ‐9; 39.3% and 31%, respectively). Interpretation These RBD participants, assessed with extensive history, demographic, cognitive, motor, sensory, and autonomic function demonstrated a lack of sex differences and high frequency of concomitant neurological abnormalities. These participants will be valuable for future longitudinal study and neuroprotective clinical trials.
Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group
Whiteway, Susan L. , Allen‐Rhoades, Wendy , Avutu, Viswatej , Indelicato, Daniel J. , Isakoff, Michael S. , Janeway, Katherine A. , Patel, Shreyaskumar , Riedel, Richard F. , Thornton, Katherine A., Ahmed, Safia K. , Avutu, Viswatej , Reed, Damon R , Riedel, Richard F , Allen-Rhoades, Wendy A , Indelicato, Daniel J , Weiss, Aaron R. , Cardona, Kenneth , Davis, Lara E. , Davis, Elizabeth J. , Livingston, J. Andrew , Reed, Damon R. , Kopp, Lisa M.

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | February 1, 2023 | Volume: 12 | Issue: 5 | Pages: 792-793

10.1089/jayao.2022.0179 | PMID 36724495 Get It

P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years
Taxonera, Carlos , Ha, Christina , Fortes, M del Pilar, Gardiner, Sean , Mundayat, Rajiv , Taxonera, C , Fortes, María del Pilar , Ghosh, Subrata , Connor, Susan Jane

Mayo Clinic

Journal of Crohn's and Colitis | January 30, 2023 | Volume: 17 | Issue: Supplement_1 | Pages: i678-i680

10.1093/ecco-jcc/jjac190.0680 Get It

Abstract Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib were demonstrated in the OCTAVE clinical programme.1,2 Here, we present an analysis of the number and causes of UC-related hospitalisations during the OCTAVE clinical programme. Methods This descriptive analysis comprised patients (pts) hospitalised for UC who received placebo or tofacitinib 10 mg twice daily (BID) in OCTAVE Induction 1&2 (NCT01465763; NCT01458951)1, and pts who received placebo, or tofacitinib 5 or 10 mg BID in OCTAVE Sustain (NCT01458574)1, or ≥1 dose of tofacitinib in OCTAVE Open (NCT01470612)2; it includes data from pts with ≤7.8 years of tofacitinib exposure. We examined the demographic and clinical characteristics, proportions, causes and other aspects of UC-related hospitalisations in pts treated with placebo or tofacitinib in the OCTAVE clinical programme. Results Overall, 1139 pts with UC were included in this analysis. Demographic and disease characteristics of pts with UC-related hospitalisations were generally similar across treatment groups in each study; most pts were &lt;40 years old, had pancolitis, a mean total Mayo score &gt;8, prior treatment with oral corticosteroids and immunosuppressants (Table 1). Ninety-five pts had UC-related hospitalisations; of whom 92 had one UC-related hospitalisation and 3 pts were hospitalised twice (Table 2). In OCTAVE Induction 1&2, OCTAVE Sustain and OCTAVE Open, 2.1%, 1.0% and 6.6% of pts, respectively, had UC-related hospitalisations with tofacitinib 10 mg BID vs 1.0% and 2.9% of pts receiving tofacitinib 5 mg BID in OCTAVE Sustain and OCTAVE Open, and 3.4% and 4.0% of pts receiving placebo in OCTAVE Induction 1&2 and OCTAVE Sustain, respectively. UC-related hospitalisations did not lead to temporary treatment discontinuations in most pts (Table 2). The most frequent cause of UC-related hospitalisations in tofacitinib- and placebo-treated pts was non-surgical UC-related events (ie, UC flares; Table 2). Conclusion UC-related hospitalisations were infrequent in the OCTAVE clinical programme, and rates were generally lower than those reported in a real-world assessment of pts with UC treated with biological therapies.3 Most hospitalised pts were aged &lt;40 years with severe disease and prior corticosteroid and immunosuppressant exposure. The most common cause of hospitalisation was non-surgical UC-related events. References: 1. Sandborn WJ et al. N Engl J Med 2017;376:1723-1736. 2. Sandborn WJ et al. Aliment Pharmacol Ther 2022;55:464-478. 3. Bressler B et al. J Crohn’s Colitis 2021;15:1694-1706.